The Best Play For Biotech’s Breakout May Not Be The Obvious Play
“Biotech stocks are breaking out,” declares the author of today’s article. When it comes to playing this breakout, however, he advises that the obvious play…
“Biotech stocks are breaking out,” declares the author of today’s article. When it comes to playing this breakout, however, he advises that the obvious play…
“Both of these biotechs deserve a lot more attention than they’ve been receiving,” asserts the author of today’s article in regards to two clinical-stage biotech…
Drugs for pain management, migraines, dry eye disease and Ebola are among those with PDUFA dates – deadlines by which the FDA must review new…
Product candidates for the treatment of excessive underarm sweating on one hand, and dry eye disease on the other, could help the two stocks highlighted…
What does the most recent data indicate about short interest in the top biotech stocks? The short answer, today’s article notes, is that “short interest…
“Call it what you will, but I think traders who’ve dug into the biotech space initially came for the COVID, then figured out there’s far…
Today’s article highlights a biotech firm that, after being relatively quiet for several years, the market may begin to take notice of as it goes…
The biotechnology sector’s outperformance amid the pandemic has led some analysts to refer to this time as the “golden period of biotechnology”. When it comes…
“We have a $5 billion market cap now. The next stage is for us to get to $20 billion,” declares the chief executive of the…
A biopharmaceutical company focused on addressing unmet needs in the fields of severe burns and other hard-to-heal wounds and a second biopharmaceutical company focused on…